Goodfellow Unit

In this episode, Dr. Paul Huggan discusses the critical topic of sepsis, its prevalence in New Zealand, and how it presents in primary care settings. He explores the differences between sepsis and standard infections, the criteria for defining sepsis, and the risk factors that make certain populations more vulnerable.

The episode emphasises early recognition using red and amber flags, alongside practical management approaches and careful, balanced use of antibiotics. It also highlights emerging research showing how ethnicity and social determinants influence sepsis risk.

In this episode Ole Schmiedel discusses Mounjaro, a new weight loss drug, with a focus on its mechanism of action, practical use, side effects, nutritional considerations, and long-term safety. The conversation provides insights into how Mounjaro differs from previous GLP-1 receptor agonists, expected weight loss outcomes, and the importance of monitoring patients while on the medication.

Massimo Giola, an infectious disease specialist, discusses genital skin problems in males.

In this episode, Dr. Alwyn D'Souza delves into advanced haematology topics relevant to general practitioners. They discuss the significance of ferritin levels, the implications of raised globulins, and the complexities surrounding paraproteins and myeloma. The conversation emphasises the importance of clinical judgment in interpreting lab results and understanding the broader context of patient health.

Professor Ngaire Kerse talks about the challenges of managing multimorbidity and medication complexity in older adults.

She discusses the definitions of multimorbidity, the vulnerabilities of older adults to medication issues, and the importance of regular medication reviews, with emphasis on appropriate prescribing and the role of healthcare professionals in supporting older adults in their medication management.

The conversation also covers specific medications like statins and aspirin, the management of hypertension, the risks associated with anticholinergic medications, and the need for equitable medication management for Māori and Pacific populations.